Autor segons l'article: Marin, Lluis Masana; Gil, Nuria Plana;
Departament: Medicina i Cirurgia
Autor/s de la URV: Masana Marín, Luis
Paraules clau: Targets Low-density lipoprotein cholesterol Inhibitor atp citrate lyase Hyperlipidemia Bempedoic acid Atp-citrate lyase Atherosclerosis Activated protein-kinase
Resum: Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence. It is a prodrug for oral administration with intracellular activation. It is activatedin liver cells and to a lesser extent in kidney cells, being absent in adipose tissue and muscle cells. Therefore, unlike statins, its potential myotoxic effect is very limited. It has recently been approved as a lipid-lowering drug in combination with diet, with statins, or with other lipid-lowering drugs in patients with hypercholesterolaemia, mixed dyslipidaemia, statin intolerance, or when these are contraindicated. The marketing of bempedoic acid implies, in clinical practice, having a new family of lipid-lowering drugs. (c) 2021 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
Àrees temàtiques: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: luis.masana@urv.cat
Identificador de l'autor: 0000-0002-0789-4954
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinica E Investigacion En Arteriosclerosis. 33 53-57
Referència de l'ítem segons les normes APA: Marin, Lluis Masana; Gil, Nuria Plana; (2021). Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clinica E Investigacion En Arteriosclerosis, 33(), 53-57. DOI: 10.1016/j.arteri.2021.02.012
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV